Fig. 2

Centrosome amplification is associated with adverse clinical factors. Centrosome amplification correlates with stage (a; p < 0.01), grade (b; p < 0.01), and subtype (c; p < 0.01). Dots represent each patient with bars representing the average ± SE. HR = hormone receptor. d-f Tumors were considered to have CA if the average number of centrosomes per cell, as assessed by pericentrin staining, was greater than 2. Centrosomes were assessed with pericentrin staining. All-cause overall survival (d), recurrence-free survival (e), and breast cancer-specific overall survival (f) are reduced in patients whose tumors demonstrated CA compared to those that did not. Log rank tests were used to calculate p-values